Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Open-label, Phase II Trial Aiming to Evaluate the Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2 Positive Breast Cancer Patients

NCT03571633 is registered in ClinicalTrials.gov with Centre Leon Berard as lead sponsor.

NCT NCT03571633
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03571633 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Open-label, Phase II Trial Aiming to Evaluate the Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2 Positive Breast Cancer Patients
Lead sponsor
Centre Leon Berard
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 6, 2018
Completion date
September 30, 2027
Enrollment
90 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive breast cancer, operable breast cancer